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Background: The increased and accelerating utilization of 3D printing in medicine opens up questions regarding
safety and efficacy in the use of medical models. The authors recognize an important shift towards point-of-care
manufacturing for medical models in a hospital environment. This change, and the role of the radiologist as a
central facilitator of these services, opens discussion about topics ranging from clinical uses to patient safety to
regulatory implications.
Results: This project first defines three groups of patients for whom 3D printing positively impacts patient care. The
steps needed for each group are described.
Conclusions: We provide our opinions regarding the regulatory role that we feel is most appropriate, balancing safety
and efficacy with the autonomy of individuals in the field to make the greatest positive impact on healthcare.
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3D printing from volumetric medical images has entered
a phase of steep growth. Although this growth has
provided an appearance that the medical modeling appli-
cation is nascent, 3D printing for surgical planning and
the use of 3D printing to develop tools to enhance med-
ical procedures has a rich history in both private practice
and academic medicine [1–15]. Medical device manufac-
turers and individual industry leaders have worked with
the U.S. Food and Drug Administration (FDA) to em-
power healthcare providers with innovative, personalized
devices that are safe and effective, while academicians
have devised and tested new interventions that would
not be possible without 3D printing [16–20]. For these
procedures, the Center for Devices and Radiological
Health (CDRH) at the Food and Drug Administration
(FDA) has reviewed and cleared 3D printed medical
devices for more than 10 years [21]. An important shift
is happening towards point-of-care manufacturing for* Correspondence: frybicki@toh.on.ca
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and the role of the radiologist as a central facilitator of
these services, opens discussion about topics ranging
from clinical uses to patient safety to regulatory
implications.
Three important regulatory milestones should be
acknowledged. First, the October 2014 FDA Public
Workshop [22], “Additive Manufacturing of Medical
Devices: An Interactive Discussion on the Technical
Considerations of 3D Printing”, held by an FDA Work-
ing Group that detailed best practices for 3D printing
quality and safety as well as an assessment of medical
devices, followed by discussion of topics ranging from
bioprinting to pharmacoprinting to metals implant
printing. Approximately 500 people attended this two-
day workshop with another few hundred watching online
from around the world. The second milestone is the FDA
“leapfrog” Draft Technical Guidance Document, “Tech-
nical Considerations for Additive Manufactured Devices”
[23], released for public comment on May 10, 2016. The
third milestone was the publication “Additively Manufac-
tured Medical Products – The FDA Perspective” [21], that
further explored the topic, including 3D printing ofis distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
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such tasks.
This document provides the authors’ collective opin-
ion, and frames the quality and safety challenges that we
perceive have emerged from state of the art medical 3D
printing. We engage the FDA and the overall community
to achieve needed clarity and specifics regarding the
potential benefits achievable through standardization.
We are determined to foster a conversation that ensures
safety and efficacy for a large number of medical models,
and to group these models with respect to risk, which
may correlate to the regulatory classification associated
with specific applications. Increasing complexity comes
from using digital data from patient anatomy to further
plan surgery and to provide 3D printed instruments,
templates, and models to facilitate surgical intervention.
For the purposes of this article the common applica-
tions today for 3D printing in medicine will be delin-
eated by their intended use, which may also roughly
correlate to how the FDA views these applications. The
three application groups to frame this discussion are:
Group I. Anatomical Models. A model representing as-
scanned anatomy intended for visualization, surgical
planning, education, informed consent and reference
during surgery. Intended use: 3D reference of anatomy
to aid surgical planningFig. 1 Anatomical Modeling Flow MapGroup II. Modified Anatomical Models. A modified
model of anatomy, simple surgical planning performed
digitally to further enhance the model, significantly
modified models. Intended use: enhanced surgical
planning and guidance
Group III. Virtual Surgical Planning with Templates.
Complex surgical planning done digitally, 3D printed
templates/models/guides produced which are
intended to guide the digital plan on the patient in
the operating room. Intended use: to augment the
surgical procedure with specific pre-planned steps
which are carried out in surgery using 3D printed
guides or templates.
To further help clarify the types of devices that exist
and regulatory ramifications for each of the three
groups, (Fig. 1) details those common steps A-M to pro-
duce a 3D printed model from medical imaging data.
Typically, the DICOM standardized format is the
presumed starting point for medical 3D printing as
described in this document.
A. Image Data Acquisition – Volumetric medical
imaging studies, for example, Computed
Tomography (CT) is used preferentially for bone or
hard tissues, and Magnetic Resonance Imaging
(MRI) may be used for cardiovascular printing and
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output of this first step.
B. 3D Visualization – For the vast majority, or all,
patients for whom 3D printing is desired, the image
interpretation (clinical reporting) will include one or
more of the following tools: multiplanar
reformatting, maximum intensity projections, and
volume rendering. Collectively, these DICOM data
manipulations are termed “3D visualization” [24].
Most patients who benefit from 3D visualization will
not require, or undergo, 3D printing. For example, a
patient who presents to Emergency Medicine with
right upper quadrant pain, suspected cholecystitis,
and a normal sonography may necessitate CT that
identifies a retrocecal appendix. Reformatted images
will assist surgical planning, but 3D printing is not
indicated, nor would it be considered temporally
reasonable in a patient who would benefit from
timely surgery. 3D visualization may be performed
using software associated with the imaging
hardware, or software from an alternate vendor.
C. Image Interpretation – The medical images are
typically interpreted before the decision to use 3D
printing to clinically improve the individual patient’s
outcome. Of note, 3D printed models can in theory
reveal additional data in patient anatomy to enhance
diagnoses, and in these situations an addendum to
the medical imaging report can be rendered.
D. Segmentation for 3D Printing – This step begins
with DICOM images from the medical imaging
study and allows for segmentation to transform
them into an unaltered surface-based 3D model that
can subsequently be used for 3D printing.
E. 3D Printing Preparation: Minor Changes – Simple
changes are made to make the model more “printable” or
to illustrate anatomical structures by labeling or coloring.
“Minor” versus “major” changes are an important
distinction and will be discussed in detail.
F. 3D Printing Preparation: Major Changes –
Modifications to the model that facilitate
intervention planning. These will be detailed further,
but include electronically resecting and
reconstructing structures, providing graft/implant
templates, or geometric mirroring to ascertain
symmetry.
G. Virtual Surgical Planning – More detailed planning
of the surgical intervention in digital space, whereby
the digital plan will be transferred to the patient by
way of 3D printed templates, guides, or models.
H. Guide/Template Design – When virtual surgical
planning is performed, the plan is transferred to the
patient with personalized instruments in the form of
templates, guides or models which need to be
designed using the output of Step G.I. Build-Preparation, Support, Slicing – Files are
processed further for the specific 3D printer to be
used, taking into account the material and additions
such as support structures and layer thickness. The
output file from this step will be input into the 3D
printer.
J. 3D Printing – Generating the output model covers a
wide range of techniques. Categorization of
differences includes how the model is constructed,
the energy source, type of materials, and other
factors [25].
K. Cleaning of Model – Depending on the 3D printing
technique, the model will need to be cleaned of
residual manufacturing materials and/or substances
required to clean the model.
L. Inspection of Model – Accuracy of the model is
paramount; this step can use qualitative and/or
quantitative measures to confirm that the 3D
printed model matches the desired input data.
M.Model Used by Physician – Typical uses for
anatomical models span a large gamut from patient
consent, to anatomic and procedural training, and
from determining the surgical plan to actually
guiding the procedure itself.
Medical Imaging: Steps A-C
Steps A-C follow current medical imaging paradigms for
image acquisition and interpretation. Hardware and
software that are used to generate medical images and
post-process them for interpretation are evaluated by
the FDA and cleared/approved for their intended use.
Segmentation & preparation for 3D printing: Steps D-E
Step D, in which DICOM images are segmented to cre-
ate STL files, should use software that is FDA cleared
for this purpose [21]. The rationale for why FDA-cleared
software should be used for creation of the STL file is
two-fold. First, a significant fraction, if not the large
majority, of this segmentation step largely parallels the
second step, 3D Visualization, from which the volumet-
ric data is post-processed to generate, for example,
multiplanar reformatted images, maximum intensity
projections, and 3D volume renderings. Just as 3D
visualization software tools require FDA clearance, so
should software used for this step, based on perceived
risk and safety. The second part of the rationale is that
the largest potential error, that is differences between
the anatomy captured within the imaging step and the
3D printed model, will arise at this step. These errors
can be attributed to either humans or software. The lat-
ter should be minimized so as to optimize patient safety.
Minor changes to the data for better 3D printing or to
highlight an area or for support are done in preparation
for 3D printing.
Fig. 2 Group I, Anatomical Models. The 3D printed model replicates
the anatomy captured by medical imaging. Patient with Crouzon
syndrome, note the characteristic calvarial deformity. a, the optic
nerve is colored red for planning intervention. b, dissected model,
after practice intervention. In this case, combined neurosurgery and
craniofacial surgery included removing and reshaping portions of
the cranial bone. Photos courtesy Dr. Kenneth E. Salyer, Dallas, TX
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While there is alteration of the medical imaging data in
the prior steps, Steps F-H differ because anatomy is al-
tered to facilitate a given, patient-specific intervention.
Modified Anatomical Models have been augmented in
some way for a patient-matched therapy. Virtual surgical
planning further extends these concepts, actually plan-
ning the surgical intervention which will be carried out
using personalized instruments, templates or models
which are designed following the completion of the
surgical planning.
3D printing: Steps I-L
The steps involved in any of the numerous 3D printing
techniques [25] cover preparation of the files before
printing, the 3D printing process itself, and model
cleanup following production and inspection of the final
model. Inspection will be dependent on the application
and need for accuracy, and could include qualitative and
quantitative measures. Some applications will test the
limits of the process and require the user to use a robust
validation to prove reliability [23, 26].
Device use: Step M
Models may be used by surgeons and many other types
of interventionists to prepare for a patient specific inter-
vention. Educating junior professionals and obtaining in-
formed consent are also often discussed. Anatomical
models and 3D printing-centric therapies have been
shown to reduce operative time for certain procedures
[27] and increase procedural accuracy in others [20].
Group I. Anatomical models
Description
These are models of anatomy to be used for educa-
tion, surgical planning, patient consent, and reference
during surgery. Pathology may be highlighted but the
anatomic data captured by volumetric imaging is not
altered (Fig. 2).
Applicable Steps: A-E, I-M
Typically derived from CT or MRI, Group I 3D models
are designed to depict the anatomic information con-
tained in the medical images, without alteration, and are
generally used for surgical planning. Examples include a
newborn with double outlet right ventricle [28] or cra-
niomaxillofacial models where tissues are not altered, for
example to plan complex procedures including congeni-
tal deformity corrections and secondary reconstruction
following trauma [2, 27, 29]. Orthopedic [30] and cardio-
vascular [19] applications include 3D printed models for
visualization and physical, hands-on simulation. The
common denominator for Group I models is that 3D
printing extends current 3D visualization and the model
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including “3D Printing Preparation” should use systems
(software and some hardware) that are cleared by the
FDA for their intended use. This includes not only the
imaging hardware/software, but also the software used
to segment the medical images from their original 2D
state into a 3D dataset usable for 3D printing (i.e., an
STL or 3MF file [31]). Regarding the steps “Build Prep –
Support, Slicing” to the end of the pathway when models
are used by healthcare professionals, work should not be
under the auspices of the FDA and do not contain what
the FDA considers to be Medical Devices [32]. Instead,
these should be managed by the entity that manufac-
tures the model (e.g., industry or hospital) and treated as
being used by doctors and other healthcare workers as a
tool in the practice of medicine.
In this scenario, Step E “3D Printing Preparation –
Minor Changes” does not make significant changes to
the anatomy, but instead refines the STL file so that it
can be printed. Since the anatomy of the printed part
has been finalized in Step D, these minor modifications
are grouped with the later steps in the workflow of gen-
erating the model after the completion of the design.
Minor modifications have the intent of not modifying
the original anatomy, but rather highlighting an area, la-
beling the model, or adding material to allow for better
3D printing production. The following are examples of
minor modifications of the models:
1. Filling holes in anatomy introduced by imaging
artifact
2. Smoothing anatomy in anatomical areas where
imaging artifact has been introduced
3. Adding structural supports to keep anatomy in
proper relation to other anatomy
4. Adding material as a “wall” around a contrast-
enhanced object (such as a vessel lumen), commonly
used for heart or vascular modeling
5. Removing known imaging artifact
6. Labeling the model
7. Cutting the model into parts for better visualization
or 3d printability
8. Adding magnets to allow for better functionality of
cut models
9. Adding color to delineate or highlight anatomical
structures
10.Grouping separate anatomical structures into a
single model file
We recognize that software packages may be designed
to do these preparation steps as well as more major
modifications spelled out in Step F. However, patients
who require substantial modifications to the anatomy
captured in the medical images should be considered inGroup II: Modified Anatomical Models. While software
used for Step E may have FDA clearance, we believe it is
not required for this intended use. Moreover, FDA
clearance of additional devices is not required for the
steps following Step E for Group I models. These
steps involve the fabrication of the 3D printed model
and subsequently the inspection and utilization of the
model for patient care. The 3D printed model which
is the output of this path is not considered a Medical
Device by the FDA [21].
Intended use
Intended for use as reference physical model of anatomy
which is the result of a volumetric medical imaging
study combined with further image processing and 3D
printing.
US FDA regulatory classification
The end product 3D printed models are not considered
Medical Devices by the FDA [21]. Steps up to and in-
cluding “D. Segmentation” do require use of a properly
cleared/approved Medical Device.
Regulatory explanation
The end product 3D printed models fall outside of the
FDA’s purview [21]. Steps up to and including “D.
Segmentation” always require use of a properly cleared/
approved Medical Device.
Example devices
Models include the following as-scanned anatomy from
an in-hospital 3D printing laboratory [33, 34] for surgical
planning: hard tissue models of the bone showing con-
genital deformity, trauma or acquired condition for re-
constructive surgery; soft tissue vascular models to show
challenging anatomy for intervention, such as an abdom-
inal aortic aneurysm under consideration for open
versus less invasive repair; renal models used to plan a
partial versus total nephrectomy.
FDA listings/clearances
Not applicable; the FDA does not consider the end-
product anatomical model to be a Medical Device. The
model is considered a hard copy output, akin to printing
medical images on film [21].
Group II. Modified anatomical models
Description
Models of anatomy whereby the anatomy has been
significantly altered from the “as-scanned” state to fur-
ther facilitate surgical planning or other intervention.
Examples include mirroring anatomy, resecting or
reconstructing anatomy, or designing grafts (Fig. 3).
Fig. 3 Group II, Modified Anatomical Models. Example modifications to the anatomy rendered from medical imaging. a and b, Patient after
trauma to the maxilla has a large osseous defect, including teeth. c and d, Model demonstrating design of a suitable graft to facilitate surgical
reconstruction. Missing bone is designed using the contralateral anatomy and output as a separate file for 3D printing a template (purple)
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3D models that fall into this category have the same
steps A-D as the non-modified anatomical models de-
scribed above. Typically, volumetric imaging is acquired
and the same steps up to segmentation are performed,
with the hardware and software all requiring clearance
for their intended uses from the FDA. The main differ-
ence between models in Group I and those in Group II
is patients who are modeled in Group II have both F
(major changes) plus E (minor changes), whereas pa-
tients who are modeled in Group I undergo minor
changes alone. Step F, unique to Group II modeling, in-
cludes further modifications to the file that are made for
a patient-specific intervention. The following are exam-
ples of major modifications:
1. Removal of segmented anatomy such as a tumor, in
order to visualize the size of the defect before
reconstruction
2. Mirroring of the dataset to provide a mirror-image
model in order to ascertain degree of symmetry or
asymmetry
3. Mirroring and “perfecting” of the dataset to provide
a model which appears to be “perfect” (a unilateral
defect has now been erased by combining half of a
mirror-image model with the half of the unaffected
original patient model),4. Digital placement of a “graft” of either alloplastic or
autogenous material into a defect and including this
on the resultant model
5. Visualizing, sizing, and simulating intervention using
another medical device digitally and subtracting said
device, its shadow, screw holes/fixation points, etc.
from the original model, leaving an imprint/pattern/
holes of some type on the model
6. Visualizing, sizing and simulating intervention using
another medical device and altering the model in
some way that includes this device
7. Designing a graft of alloplastic or autogenous
material and printing out the model with an
indication of this graft or a printout of the new graft
itself. An example includes a patient with a
cranioplasty defect and filling the defect with a
perfectly-fitting implant template which will be used
to guide harvest of autogenous material or shaping/
manufacturing of alloplastic material.
When one or more of these Step F, or major modifica-
tions, is made, or a comparable modification that changes
the patient’s anatomy in planning for a specific interven-
tion, the software used to make that modification should
be FDA cleared for this intended use, and the printed
model should also be considered a Medical Device. Subse-
quently, the device itself will require 3D printing. When
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printer) and the software used to drive the hardware
should be FDA cleared for these intended uses. The ra-
tionale is that a large number of 3D printing technologies,
with varying levels of performance and capabilities, could
be otherwise used to print medical devices that could, in
turn, be used for more intensive guidance of treatment.
Intended use
Intended for use as a reference anatomical model by a
surgeon/interventionist to plan a surgical intervention.
Modifications made to the anatomy are intended for
patient-specific intervention planning and/or guidance
during surgery.
US FDA regulatory classification
These models are considered Medical Devices [23].
Some of these are Class I Exempt Medical Devices (i.e.,:
FDA Product Code HWT – Template for Clinical Use)
while some of these (e.g., cranioplasty templates and
others) would be up-classified to the level of the implant
systems they support, typically Class II.
Regulatory explanations
For a commercial company to legally market and sell a
product, the manufacturer must be registered with the
FDA, have an FDA-compliant quality system and list the
product with the FDA. FDA pre-market approval (i.e.,:
510(k)) would not be required for a Class I ExemptFig. 4 Group III, Virtual Surgical Planning with Templates. a, 3D printed mo
Radiology interpretation and the 3D model helped decide on a treatment pla
plan was designed for a free fibula graft, that is, a vascularized fibula graft con
(green). c, virtual placement of the fibula graft (green bone segments); grey an
surgery. d, Virtual placement of a denture supported on this framework, all to
printed templates to enable precise osteotomies of the fibula and customized
used in surgery, enabling what otherwise would not be possible within the sc
DDS, MD, Chief, Oral and Maxillofacial Surgery, Lennox Hill Hospital, NY, Newdevice, but would likely be required for any Class II
devices. The entity is subject to upholding the FDA’s
Quality Systems Regulations (QSR) and can be inspected
by the FDA at their leisure.
For a hospital entity, the hospital should seek to use a
cleared Medical Device “system” for production of these
types of models in a hospital setting.
Example FDA listings/clearances
Materialise HeartPrint – [35]
3D Systems ClearView Anatomical Model – [36]
Anatomical models sold by numerous companies such
as 3D Systems [37], Materialise [38], DePuy Synthes
[39] and Stryker [40].
Group III. Virtual surgical planning with templates
Description
Virtual Surgical Planning is a digital process that typic-
ally begins with a volumetric medical imaging study.
Proven applications include bone reconstructive surgery
such as repair of congenital defect, or after trauma to
the craniomaxillofacial region [16–18] or other ortho-
pedic applications. Once surgery is planned digitally,
templates and guides are then designed to transfer the
surgical plan from the computer to the patient (Fig. 4).
Models of anatomy may be present but more important
are the 3D printed templates/guides/models that enable
transfer of a digital surgical plan to patient care. Anotherdel of patient with aggressive lesion of the mandible, colored in red.
n including full thickness bony resection. The surgical reconstruction
taining bone and soft tissue. b, Cutting paths for the bone resection
d red cylinders represent dental implants to be placed at the time of
be planned and accomplished a single-stage procedure. e and f, 3D
dental implant positions were produced with stereolithography and
ope and time of a single intervention. Photos courtesy David L. Hirsch,
York
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for templating total joint arthroplasty whereby the surgi-
cal simulation helps choose size/model of the implant
and the template properly positions the implant or pre-
pares the patient’s bone structure, taking into account
the patient’s unique anatomy and physiology.
Applicable Steps: A-M
Intended use For those virtual surgical planning devices
with a software component, the intended use may also
include the following: intended for use as a software
interface and image segmentation system for the transfer
of CT or MRI data. The input data file is processed and
the result is an output data file that may then be used as
input data for a 3D printer that produces anatomical
models, templates, and surgical guides. Also intended as
a pre-operative software tool for simulating/evaluating
surgical treatment options, or templating for total joint
arthroplasty. FDA’s product code PBF, “orthopedic surgi-
cal planning and instrument guides” [41] combines both
the 3D printed output guides/templates along with the
surgical planning software. It is expected that this will
happen more frequently as further applications arise for
personalized surgical guidance.
US FDA regulatory classification These products are
primarily considered Class II Medical Devices subject to
premarket clearance requirements, most times requiring
a 510(k). Class III Medical Device(s) requiring a Premar-
ket Approval (PMA) have also been approved in this
area for use in templating Class III implant systems.
Regulatory explanations
For a commercial company to legally market and sell
the product, the manufacturer must a) have clearance
(510(k)) or approval (PMA) for the product, b) be regis-
tered with the FDA, c) have an FDA-compliant quality
system, and d) list the product with the FDA.
For a hospital entity, the hospital should seek to use
an FDA-cleared Medical Device “system” for production
of these types of models/templates/guides/surgical plans.
Example FDA listings/clearances
Class II Clearances:
Materialise ProPlan/SurgiCase – 510(k) K111641 [42]
Zimmer Biomet Signature – 510(k) K133162 [43]
3D Systems VSP– 510(k) K120956 [44]
DePuy Synthes TruMatch– 510(k) K110397 [45]
Review
The number of medical 3D printing applications con-
tinues to grow, as does the number of users dedicated toimproving patient care pathways. The authors recognize
potential divergent pathways for patient safety and the
efficacy of medical models, and they provide recommen-
dations for dialogue on best methods to integrate 3D
printing to medical practice. 3D printing applications are
separated into three groups: Anatomical models, Modi-
fied anatomical models, and Virtual surgical planning
with templates. These groups are explicitly defined with
recommendations on optimizing safety and efficacy for
each. Professionals engaged in 3D printing must main-
tain a high level of training and competence, and we rec-
ommend the use of FDA cleared software and hardware
when appropriate.
Discussion
Hospitals making parts versus companies selling medical
devices
In the United States, the FDA’s Center for Devices and
Radiological Health (CDRH) is responsible for regulating
firms who manufacture, repackage, relabel, and/or im-
port medical devices sold in the United States [32, 46,
47]. In practical application the FDA regulates those
who market and sell devices to the U.S. market; these
are the Original Equipment Manufacturers (OEMs) of
medical devices, for example Johnson & Johnson, Stry-
ker, and Medtronic. The FDA does not typically regulate
the users of these devices, although there are likely ex-
ceptions to this rule. While hospitals are not typically
under the FDA’s purview, in the U.S. many are often
accredited by the independent Joint Commission
(formerly the Joint Commission on Accreditation of
Healthcare Organizations – JCAHO [47]). The Joint
Commission audits and provides accreditation to hospi-
tals providing quality medical care.
Other countries may have similar or different views on
what does or does not constitute a medical device, from
a regulatory standpoint. We suggest that users outside of
the U.S. contact their local authority to ascertain who
regulates medical devices and to determine what is
regionally appropriate.
Areas of potential concern
We recognize that, to date, physicians who have been
utilizing 3D printing for all three groups defined above
have held very high standards, and many have benefited
from FDA oversight. Several reasons exist today which
have created circumstances where a future safety risk is
real. These include:
a) Freeware software of unknown quality/pedigree
being used to process patient images.
b) Freeware software of unknown quality/pedigree
being used to plan, simulate, or perform “virtual
surgery”
Christensen and Rybicki 3D Printing in Medicine  (2017) 3:1 Page 9 of 10c) 3D printers are now available almost everywhere,
from a $100 model to a $1,000,000 model. Lower
end models may not be suited towards the
fabrication of quality medical devices; however, users
can adopt technologies because they are inexpensive.
d) Unknown expertise of operators using non-cleared
software devices is of concern, particularly if models
are intended to guide a medical intervention.
Relating specifically to software, the FDA has given
guidance in the past years for Commercial off the Shelf
Software (COTS) and Software of Unknown Provenance
(SOUP), relating to software that may be used as part of
a medical device but with unknown development path
and/or safety record [26, 48]. The issue is not only
within the COTS/SOUP software, but also when it
serves a key role in a process the issue is with the rest of
the software “system”, and potentially negative/unknown
effects on the whole of the process.
The call for standardization and guidelines
We recognize that, even with clarity regarding the ma-
terial presented above, several questions remain. These
too are important to tackle given the exponential growth
in the field. The first question relates to a possible differ-
ent set of recommendation for individuals working in-
side a clinical facility (e.g., hospital-based 3D printing)
versus obtaining models from an outside vendor. We be-
lieve that there should be no distinction. The rationale is
that both sets of professionals should have the same
standards, and provide the same profile of safety and
efficacy. As utilization of 3D printing in medicine
increases from both groups, rigorous guidelines are
needed to ensure that the field progresses with a “pa-
tient-first” interest as the top priority.
Today, medical 3D printing has largely focused on
niche applications, and members of the relatively small
community have held very high quality standards. There
are published metrics for model reproducibility, and
commercial vendors also have proprietary algorithms to
ensure that medical models have the greatest positive
impact. As a community grows, known areas for which
there can be compromises in quality will likely be mag-
nified by the sheer number of users. This will be com-
pounded by the development and use of software or
hardware that have not undergone rigorous vetting in
the scientific and regulatory community.
Many of the concepts presented here lead the authors
to believe that there exists a need for standardization
across clinical sites using 3D printing technologies.
Standardization would ensure the first steps towards up-
holding patient safety as paramount. It would also help
to ensure that hospitals are following best practices from
both the operational standpoint, and the FDA regulatorystandpoint. There is also a large need for two sets of
guidelines. The first is technical guidelines for models in
Groups I, II, and III that will meet physician and patient
needs. The second set are clinical guidelines that outline
appropriateness of 3D printing for specific clinical sce-
narios, akin to those now produced by the American
College of Radiology Appropriateness Criteria®.
Conclusion
E plurbus unum (translation “out of many, one”) generally
refers to the “melting pot” of many individuals, for ex-
ample from different ancestries, religions, and races. 3D
printing in medicine will emerge as a universal tool, a
melting pot for the delivery of medical care that integrates
medical information from volumetric imaging devices.
The relatively small number of users will expand. More
widespread enthusiasm will ultimately be fueled by reim-
bursement. During this transition, we are obligated to pay
particular attention to quality medical modeling, and we
will rely on the FDA to ensure safety and efficacy.
Very close collaboration between academics, industry,
and the FDA is paramount to ensure safety for those
U.S. patients whose quality of life will be improved by
3D printing. This article is designed to foster that collab-
oration and to encourage dialogue. Similarly, profes-
sionals engaged in 3D printing must maintain a high
level of training and competence, and we believe that
they should use FDA cleared software and hardware
when appropriate. Education and clinical practice that
focus on alternate, non-cleared software and hardware
should be discouraged. For models designed to identi-
cally emulate patient anatomy, all hardware used to gen-
erate the image and post-process the relevant anatomy
should be cleared by the FDA, while those steps related
to the fabrication alone should be done with care, but
should ultimately be monitored by the medical team car-
ing for the patient in the Practice of Medicine. Patients
for whom anatomy is altered significantly require use of
software/hardware for that intended use which is cleared
as a medical device. 3D printing has emerged as revolu-
tionary paradigm shift for helping surgeons and inter-
ventionalists perform procedures in a more informed
way, but for these patients and keeping safety at the
forefront, all steps should be considered under the
auspices of the FDA.
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